Acorda Therapeutics, Inc.

Total Valuation

Acorda Therapeutics, Inc. carries a market capitalization of 12,421.00, placing it among publicly traded companies globally. Its enterprise value stands at 202.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Acorda Therapeutics, Inc. currently has 1.24M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.14, and the price-to-book ratio stands at -0.01.

Enterprise Valuation

On an enterprise value basis, Acorda Therapeutics, Inc. trades at an EV/EBITDA multiple of 368.35 and an EV/FCF ratio of 147.18.

Financial Position

Acorda Therapeutics, Inc. maintains a current ratio of 0.22, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -105.46, indicating conservative leverage, while an interest coverage ratio of 0.02 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Acorda Therapeutics, Inc.'s stock has declined approximately -99.9382% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 7.10.

Income Statement

Over the trailing twelve months, Acorda Therapeutics, Inc. generated 115.66M in revenue and converted that into -263.42M in net income, yielding earnings per share of -212.10. EBITDA reached 551,000.00, while operating income came in at -24.08M.

Balance Sheet

Acorda Therapeutics, Inc. holds 9.36M in cash and equivalents against 195.92M in total debt, resulting in a net debt position of 182.11M. Total book value stands at -1.22B, with working capital of -175.48M providing operational flexibility.

Cash Flow

Acorda Therapeutics, Inc. produced -27.15M in operating cash flow over the past twelve months. After subtracting -264,000.00 in capital expenditures, free cash flow totaled -27.41M - equivalent to -22.07 per share.

Margins

Acorda Therapeutics, Inc. operates with a gross margin of 86.38, reflecting its pricing power and cost economics. The operating margin of -20.82 and net profit margin of -227.75 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Acorda Therapeutics, Inc.'s most recent stock split took place on June 5, 2023 with a 20:1 split ratio.

Scores

Acorda Therapeutics, Inc. posts an Altman Z-Score of -31.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.